Reblozyl
Phase 2Small molecule
Reblozyl is one of 48 small molecule programs targeting Anemia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Anemia
#DrugCompanyPhaseTrials
1Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Rayos
RRoxane Laboratories
Approved
Orgovyx
Sumitomo Pharma America, Inc.Approved
Leustatin
EMD SeronoApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Campath
GGenzyme, a Sanofi Company
Phase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Aldactone
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reblozyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEuroBloodNet Association